Packaging World |
Aptar Pharma dose indicator selected for new asthma combination therapy
Packaging World It is indicated for the maintenance treatment of asthma in patients aged 12 years and over, and in adults whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting beta2-agonist (SABA), and in those patients who are … |
View full post on asthma – Google News